Matt Larew

Stock Analyst at William Blair

(0.28)
# 4,492
Out of 4,663 analysts
12
Total ratings
33.33%
Success rate
-22.2%
Average return

Stocks Rated by Matt Larew

Maravai LifeSciences Holdings
Nov 8, 2024
Downgrades: Market Perform
Price Target: n/a
Current: $4.63
Upside: -
Amedisys
Jul 1, 2024
Downgrades: Market Perform
Price Target: n/a
Current: $90.00
Upside: -
Ginkgo Bioworks Holdings
May 10, 2024
Downgrades: Underperform
Price Target: n/a
Current: $6.45
Upside: -
AptarGroup
Apr 29, 2024
Upgrades: Outperform
Price Target: n/a
Current: $166.90
Upside: -
Bio-Techne
Aug 28, 2023
Initiates: Outperform
Price Target: n/a
Current: $66.37
Upside: -
Avantor
Jul 31, 2023
Downgrades: Market Perform
Price Target: n/a
Current: $19.72
Upside: -
InnovAge Holding
Sep 22, 2021
Downgrades: Market Perform
Price Target: n/a
Current: $4.78
Upside: -
MaxCyte
Aug 24, 2021
Initiates: Outperform
Price Target: n/a
Current: $3.33
Upside: -
Twist Bioscience
Jun 29, 2021
Initiates: Outperform
Price Target: n/a
Current: $41.32
Upside: -